Overview of the Journals

Journal Information at a Glance

Together, these three journals represent the highest level of dermatology scholarship across North America and Europe, offering complementary perspectives from foundational science to real-world clinical implementation.

Key Research Domains: Integrated Analysis

I. Advances in Atopic Dermatitis (AD) Management

1. Infection Risk and Long-Term Safety

Source: JEADV – Global Cohort Study

A large-scale analysis using the TriNetX global health database evaluated infection risk among patients receiving dupilumab.

• Study population: 10,913 matched patient pairs

• Follow-up duration: Up to 3 years

• Key findings:

• Significant reduction in 32 categories of infections

• Hazard ratios ranged from 0.39 to 0.68

Clinical implication:
Both cutaneous and systemic infection risks were reduced, supporting dupilumab as a suitable option for patients with heightened susceptibility to infections.

2. Early Prediction and Preventive Strategies

Source: JEADV – Danish Birth Cohort

An innovative cohort study explored early-life predictors of AD development.

• Key observation: Palmar crease thickening at 2 months of age

• Risk association:

• AD development at 1 year: HR 2.82

• Combined with TARC/CCL17 biomarkers: HR increased to 5.66

Clinical value:
This simple, non-invasive screening approach may enable earlier identification of high-risk infants and facilitate preventive intervention strategies.

3. Metabolic Disease and Inflammatory Skin Disorders

Source: JAAD + JEADV

Emerging evidence highlights the dual dermatologic benefits of GLP-1 receptor agonists.

• Mechanism:

• Direct inhibition of the NF-κB pathway

• Downregulation of TNF-α, IL-17, and IL-23

• Clinical outcomes:

• Improvement in psoriasis and hidradenitis suppurativa lesions

Target population:
Patients with inflammatory dermatoses complicated by metabolic comorbidities.

4. Management of Refractory Atopic Dermatitis

Source: JEADV – Real-World Evidence

• Therapeutic strategy: Lebrikizumab as rescue therapy

• Indication: AD refractory to upadacitinib

• Outcome: Favorable real-world effectiveness

Clinical relevance:
Provides an alternative pathway for patients who fail JAK inhibitor therapy.

II. Optimization of Alopecia Areata Treatment

1. Sequential JAK Inhibitor Therapy

Source: JAMA Dermatology + JEADV

• Principle: Failure of one JAK inhibitor does not preclude response to another

• Evidence:

• 13 patients achieved significant hair regrowth after switching agents

• Available options:

• Ritlecitinib, baricitinib, upadacitinib

Clinical takeaway:
Sequential therapy expands treatment flexibility for refractory alopecia areata.

2. Combination Therapy Approaches

Source: JEADV – Real-World Study

• Regimen: Baricitinib combined with corticosteroids

• Results: Superior efficacy compared to monotherapy

• Safety: Well tolerated

Indication:
Moderate to severe alopecia areata.

III. Standardization in Aesthetic Dermatology

1. Expert Consensus on Skincare Ingredients

Source: JAAD – Delphi Consensus Study

This framework provides clinicians with evidence-based guidance amid a saturated skincare market.

2. Emerging Technologies and AI Limitations

Source: JAAD + JEADV

• Current challenge:

• Underrepresentation of darker skin tones (10.2%)

• Diagnostic accuracy only 15%

• Future direction:

• Diverse training datasets

• Ethical and regulatory oversight

Clinical implication:
Ensuring fairness and reliability in AI-assisted dermatologic diagnosis remains critical.

IV. Precision Management in Skin Oncology

1. New Insights into Melanoma

Source: JAAD – Prospective Study

• Finding:

• Patients with BMI ≥30 kg/m² diagnosed at earlier stages (OR 1.93)

• Explanation:

• Increased healthcare utilization leading to earlier detection

Conclusion:
Obesity is not an independent adverse prognostic factor in melanoma.

2. Optimized Therapy for Basal Cell Carcinoma

Source: JAAD – Phase III Trial

• Treatment:

• 10% 5-aminolevulinic acid gel + red light PDT

• Design:

• Randomized, double-blind, multicenter

• Indication:

• Superficial BCC

V. Safety Considerations in Acne Treatment

1. Growth and Development Outcomes

Source: JAAD – Large Cohort Study

• Isotretinoin findings:

• No impact on final adult height

• Temporary growth velocity reduction during treatment

Clinical guidance:
Standard dosing regimens remain safe; caution warranted in very young patients receiving high doses.

2. Topical Therapy–Related Shedding

Source: JAAD – Multicenter Prospective Study

• Minoxidil-induced shedding:

• Onset: ~2 weeks

• Peak: 4 weeks

• Recovery: By 12 weeks

Patient education:
Crucial to prevent unnecessary discontinuation.

VI. Innovations in Neuromodulatory Therapies

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Source: JAMA Dermatology – High-Quality RCT

• Indication: Rosacea

• Benefits:

• Reduced erythema and flushing

• Improvement in anxiety, depression, sleep quality, and migraine

• Durability: Sustained at 24 weeks

• Safety: Rare adverse events

VII. Drug Safety Surveillance

1. Cardiovascular Risk with JAK Inhibitors

Source: JEADV – Global Cohort

• Monitoring focus:

• Cardiovascular events

• Thromboembolic risk

• Clinical approach:

• Individualized risk–benefit assessment

2. Infection Risk: Biologics vs JAK Inhibitors

Source: JEADV – BioDay Study

Provides comparative safety data to inform therapeutic decision-making in AD.

VIII. Translational Innovation and Digital Dermatology

• Multi-task AI diagnostic models

• Large language models in hidradenitis suppurativa assessment

• Dermoscopy + AI workflows

• Advanced digital imaging, including line-field confocal OCT

Real-World Evidence Highlights

Editorial Summary

This integrated review synthesizes high-impact dermatology research from JAAD, JAMA Dermatology, and JEADV, emphasizing clinically actionable insights supported by randomized trials, real-world evidence, and expert consensus.

Core value:

• Bridging research and practice

• Supporting evidence-based decision-making

• Advancing patient-centered dermatologic care

Disclaimer:
This content is intended for medical professionals. Clinical decisions should be made based on individual patient characteristics and current clinical guidelines.